Circulating CCL2 was reported to decrease in SSc patients after treatment with prostaglandin E1, although no difference in this chemokine levels was found in patients with/without DUs, teleangectasias, or according to NVC patterns, either before or after therapy [165]. Here, CCL2 is linked to systemic sclerosis.